Everbright International Trade Center
West side of the second floor No. 47, Jida Haibin South Road Xiangzhou District
Zhuhai 519015
China
86 75 6388 2955
https://www.sailong.cn
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 483
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Jian Feng Li | Deputy GM & Director | N/A | N/A | 1981 |
Ms. Zhang Xu | Board Secretary, Deputy GM & Director | N/A | N/A | 1986 |
Mr. Xing Wang | Deputy General Manager | N/A | N/A | 1983 |
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.
Sailong Pharmaceutical Group Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.